Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01780454 · ClinicalTrials.gov registry record · Phase 1

Renal Allograft Tolerance Through Mixed Chimerism

A Phase 1 study, sponsored by Massachusetts General Hospital.

Completed
Registry status
Phase 1
Development phase
2
Enrollment target

NCT01780454: Completed Phase 1 study, sponsored by Massachusetts General Hospital.

NCT01780454 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01780454, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Phase 1
Development phase
2 participants
Enrollment target

Study Summary

This study will examine the safety and effectiveness of a combination kidney and bone marrow transplant from a haplo-identical related donor. An investigational medication and other treatments will be given prior to and after the transplant to help protect the transplanted kidney from being attacked by the body's immune system

Primary Outcome

The primary endpoint is induction of transient mixed chimerism and renal allograft tolerance without "engraftment syndrome" or "acute kidney injury"

Interventions

  • DRUG Rituximab
  • RADIATION Total Body Irradiation
  • DRUG MEDI-507
  • RADIATION Thymic Irradiation

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2013-03
Est. Completion 2020-06
Phase Phase 1
Massachusetts General Hospital

2,032 total trials

What the finished NCT01780454 record still lists

NCT01780454 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 4 interventions - of which Rituximab is the first listed.

NCT01780454 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01780454 about?

NCT01780454 is a clinical study titled "Renal Allograft Tolerance Through Mixed Chimerism". This study will examine the safety and effectiveness of a combination kidney and bone marrow transplant from a haplo-identical related donor. An investigational medication and other treatments will be given prior to and after the transplant to help protect the transplanted kidney from being attacked...

What is the current status of trial NCT01780454?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2013-03. Estimated completion is 2020-06.

What interventions are being tested in trial NCT01780454?

The interventions under investigation include: Rituximab (DRUG), Total Body Irradiation (RADIATION), MEDI-507 (DRUG), Thymic Irradiation (RADIATION).

Who is sponsoring clinical trial NCT01780454?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01780454's enrollment target sits among peer trials

2 2000th of 2000 the lowest of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01780454, the US trial registry maintained by the National Library of Medicine. NCT01780454 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.